Behcet Disease Patients With Pulmonary Endoarterectomy: Outcomes of Program of Inspiratory Msucle Trianing

June 17, 2026 updated by: Ali Mohamed Ali ismail, Cairo University
physical complications are common in Behcet disease patients with pulmonary endoarterectomy, so outcomes of program of inspiratory msucle trianing must be investigated

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Detailed Description

Forty Behcet disease patients with pulmonary endoarterectomy will be assigned to group I or Group II. the patients will be adolescents, 20 patients in the group. Group I will recive program of inspiratory msucle trianing for 12 weeks (one session daily, except the last two days of the week) Group II will act waitlist group.

Study Type

Interventional

Enrollment (Estimated)

40

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

  • Egypt
    • Dokki
      • Giza, Dokki, Egypt
        • Recruiting
        • Cairo University
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • adlescent patients
  • complain Behcet disease
  • after pulmonary endoarterectomy

Exclusion Criteria:

  • chronci cardiac diseases
  • psychic disease
  • mental disease

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: group number 1
twenty Behcet disease patients with pulmonary endoarterectomy will be will recive program of inspiratory msucle trianing for 12 weeks (one session daily, except the last two days of the week)
Other: inspiratory muscle trianing
twenty Behcet disease patients with pulmonary endoarterectomy will be will recive program of inspiratory msucle trianing for 12 weeks (one session daily, except the last two days of the week)
No Intervention: group number 2
twenty Behcet disease patients with pulmonary endoarterectomy will act as wailisting group for 12 weeks

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
forced vital capacity
Time Frame: it will be measured after 12 weeks
it si a pulmaonry fucntion test
it will be measured after 12 weeks

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
forced expiratory volume
Time Frame: It will be measured after 12 weeks
it will be assessed in first second of expiration
It will be measured after 12 weeks
ratio of force vital capcity to first-second-expiratory forced expiration volume
Time Frame: It will be measured after 12 weeks
it is a pulmoanry fucntion test
It will be measured after 12 weeks
fatigue severity scale
Time Frame: It will be measured after 12 weeks
it will assess fatigue perception
It will be measured after 12 weeks
child health questainanire parent form assessment of phsyical summary
Time Frame: it will be measured after 12 weeks
it is an assessment of quality of life
it will be measured after 12 weeks
child health questainanire parent form assessment of mental summary
Time Frame: It will be measured after 12 weeks
it is an assessment of quality of life
It will be measured after 12 weeks
Ruffier index
Time Frame: It will be measured after 12 weeks
it an indiactor for cariorespiratory fitness
It will be measured after 12 weeks
maxinmal inspiration pressure
Time Frame: It will be measured after 12 weeks
it is an indicator for isnpiratory msucular stength
It will be measured after 12 weeks
maxinmal expiration pressure
Time Frame: It will be measured after 12 weeks
it is an indicator for expiratory msucular stength
It will be measured after 12 weeks
six minute walk test
Time Frame: It will be measured after 12 weeks
distance covered during this test will be assessed
It will be measured after 12 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Cairo University

Investigators

  • Principal Investigator: Ali MA Ismail, lecturer, Cairo University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

May 6, 2026

Primary Completion (Estimated)

September 6, 2026

Study Completion (Estimated)

September 6, 2026

Study Registration Dates

First Submitted

June 17, 2026

First Submitted That Met QC Criteria

June 17, 2026

First Posted (Actual)

June 23, 2026

Study Record Updates

Last Update Posted (Actual)

June 23, 2026

Last Update Submitted That Met QC Criteria

June 17, 2026

Last Verified

June 1, 2026

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • IRB000-14233-81

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Behcet Disease

Clinical Trials on inspiratory muscle trianing

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Mali

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe